Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say about it.

The FDA has approved a breakthrough preventative treatment for HIV that could change the course of the AIDS epidemic. But ...

Japan’s lack of generic PrEP options has made therapies inaccessible to most patients. Access to newer HIV therapies remains a major challenge in the global HIV treatment landscape, largely due to ...

This discovery could make treatment for an eye disease affecting millions with diabetes more accessible and affordable.

A federal judge has ruled that recent mass layoffs at the U.S. Department of Health and Human Services were likely unlawful ...